Ironwood Pharmaceuticals

Ironwood Pharmaceuticals company information, Employees & Contact Information

At Ironwood Pharmaceuticals, we are committed to advancing the treatment of GI diseases and redefining the standard of care for GI patients. As a pioneer and champion in the development of a market-leading therapy for IBS-C and CIC, we are singularly focused on advancing the treatment of GI diseases and continue to challenge what has been done before to shape what the future holds. So, we named ourselves after the Ironwood tree, which can live for thousands of years in the harshest desert, creating a shaded microclimate in which life thrives. Iron, like science, is undeniable and strong. Wood, like artistry and humanity, is flexible, resilient and versatile. The two words together represent our passion for making a positive impact on the health – and lives- of GI patients, their families and communities. Our core values: •Transform Patient Lives: Leverage our insights, capabilities, and expertise to see the most critical patient needs. •Innovate Meaningfully: Think boldly, experiment proactively, and take initiative to create new possibilities in the GI world. •Challenge and Collaborate: Encourage different opinions and points of views in decision-making. •Practice Humanity: Recognize that our people are the cornerstone of Ironwood. •Own The Outcome: Honor our commitments to our patients, stakeholders, and one another by upholding a performance-driven culture.

Company Details

Employees
292
Founded
-
Address
100 Summer Street, Boston,ma 02110,united States
Phone
617-621-7722
Email
in****@****rma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Boston, MA
Looking for a particular Ironwood Pharmaceuticals employee's phone or email?

Ironwood Pharmaceuticals Questions

News

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - Ironwood Pharmaceuticals

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide - Business Wire

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide Business Wire

Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation - Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation Ironwood Pharmaceuticals

Ironwood Completes Squeeze-Out Merger With VectivBio - citybiz

Ironwood Completes Squeeze-Out Merger With VectivBio citybiz

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2 - Yahoo Finance

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2 Yahoo Finance

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call - FinancialContent

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call FinancialContent

U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS® (linaclotide) for Adults with Chronic Idiopathic Constipation - PR Newswire

U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS® (linaclotide) for Adults with Chronic Idiopathic Constipation PR Newswire

Check out Ironwood Pharmaceuticals's stock price (IRWD) in real time - CNBC

Check out Ironwood Pharmaceuticals's stock price (IRWD) in real time CNBC

Ironwood Pharmaceuticals Announces Alignment of Workforce with Priority Growth Platforms - Fierce Biotech

Ironwood Pharmaceuticals Announces Alignment of Workforce with Priority Growth Platforms Fierce Biotech

Linzess Approved for IBS and Constipation - Medical Professionals Reference

Linzess Approved for IBS and Constipation Medical Professionals Reference

Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance - Business Wire

Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance Business Wire

Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO® (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout - Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO® (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - Business Wire

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance Business Wire

Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases - Business Wire

Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases Business Wire

Top Ironwood Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant